DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis.
DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis.
复制标题
DOI：
10.1038/ncomms14252
复制
发表时间：
2017-02-06
影响因子：
16.6
通讯作者：
Markovitz DM
中科院分区：
文献类型：
--
作者：
Mor-Vaknin N;Saha A;Legendre M;Carmona-Rivera C;Amin MA;Rabquer BJ;Gonzales-Hernandez MJ;Jorns J;Mohan S;Yalavarthi S;Pai DA;Angevine K;Almburg SJ;Knight JS;Adams BS;Koch AE;Fox DA;Engelke DR;Kaplan MJ;Markovitz DM
Novel therapeutics are required for improving the management of chronic inflammatory diseases. Aptamers are single-stranded RNA or DNA molecules that have recently shown utility in a clinical setting, as they can specifically neutralize biomedically relevant proteins, particularly cell surface and extracellular proteins. The nuclear chromatin protein DEK is a secreted chemoattractant that is abundant in the synovia of patients with juvenile idiopathic arthritis (JIA). Here, we show that DEK is crucial to the development of arthritis in mouse models, thus making it an appropriate target for aptamer-based therapy. Genetic depletion of DEK or treatment with DEK-targeted aptamers significantly reduces joint inflammation in vivo and greatly impairs the ability of neutrophils to form neutrophil extracellular traps (NETs). DEK is detected in spontaneously forming NETs from JIA patient synovial neutrophils, and DEK-targeted aptamers reduce NET formation. DEK is thus key to joint inflammation, and anti-DEK aptamers hold promise for the treatment of JIA and other types of arthritis. DEK is a secreted protein abundant in the synovia of patients with juvenile idiopathic arthritis. Here the authors show DEK is important for neutrophil extracellular trap formation and joint inflammation, and demonstrate therapeutic efficacy of DEK-targeting aptamers in a mouse model of arthritis.
